NSCLC

This phase 2 trial is testing the targeted drug brigatinib in 118 people with ALK-positive non-small cell lung cancer that has spread or cannot be surgically removed. The main goal is to see how long the cancer stays under control before it progresses. Researchers are also studyi…

This phase 2 trial tested two drugs, osimertinib and gefitinib, in 156 people with advanced EGFR-mutant lung cancer. The goal was to see if using blood tests (liquid biopsies) to detect genetic changes could help decide when to switch treatments, compared to standard scans. The s…

This study tested a combination of two immunotherapy drugs (eftilagimod alpha and pembrolizumab) in 187 people with advanced lung cancer or head/neck cancer that had not been treated or had stopped responding to prior therapy. The goal was to see if the combination could shrink t…

This phase 3 trial tested a portable device that creates electric fields to disrupt cancer cell division in 291 people with stage 4 non-small cell lung cancer that had worsened after initial chemotherapy. Participants wore the device on their chest while continuing standard treat…

This Phase 3 study tested whether adding bevacizumab (Avastin) to erlotinib (Tarceva) works better than erlotinib alone for Chinese patients with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations. Over 300 patients were randomly assigned to one of the t…

This study tested whether a procedure called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows signs of remaining cancer (minimal residual disease, or MRD). 37 patients with stage IV NSCLC received LAT to all visib…

This early-phase trial tested a new oral drug called JAB-21822, alone or with cetuximab, in 29 adults with advanced solid tumors (like lung or colorectal cancer) that have a specific KRAS G12C mutation. The main goals were to check safety and find the right dose. Participants had…

This phase 2 trial tested the drug furmonertinib in 24 people with advanced non-small cell lung cancer (NSCLC) that has EGFR mutations and spread to the brain. The goal was to see how long the drug could keep brain tumors from growing. Participants took a daily pill, and research…

This early-stage trial tested a new drug called CFT1946, alone or with other drugs, in 89 adults with solid tumors that have a BRAF V600 mutation, including melanoma, lung, colon, and thyroid cancers. The main goals were to check safety and find the best dose. The study is comple…

This Phase 2 trial tested whether adding the experimental drug OSI-906 to the standard targeted therapy erlotinib (Tarceva) could help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. The study enrolled 88 people who had not received prior c…

This early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …

This study tested whether a simple breath test can predict if cancer patients will respond to immunotherapy drugs. Researchers used an electronic nose device to analyze breath samples from 190 patients with lung, melanoma, kidney, bladder, or head and neck cancers. The goal is to…

This study looked at whether a blood test measuring DNA fragments can detect leftover cancer after lung cancer surgery. Researchers followed 133 patients with early-stage lung cancer for one year after their operation. The goal was to see if changes in the DNA test could predict …

This study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…

This completed observational study looked at 3,000 people with advanced non-small cell lung cancer who received immunotherapy plus chemotherapy. Researchers built a model using chest CT scans, lung function tests, and immune markers to predict how well the treatment would work an…